Aeterna Zentaris Company Overview
Aeterna Zentaris
About Aeterna Zentaris
Aeterna Zentaris (NASDAQ:AEZS) is a biopharmaceutical company focused on developing and commercializing novel treatments in oncology, endocrinology and women's health. With a pipeline of innovative therapies aimed at addressing unmet medical needs, the company's research and development strategy prioritizes the advancement of its lead candidates. Aeterna Zentaris is dedicated to improving patient outcomes and enhancing quality of life through groundbreaking scientific research. Its objective is to become a key player in the biopharmaceutical field by delivering effective solutions for conditions with significant treatment gaps.
What is Aeterna Zentaris known for?
Snapshot
1990
Year founded
21
Employees
South Carolina, United States
Head office
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Aeterna Zentaris
- Macimorelin, an orally active ghrelin agonist for diagnosing adult growth hormone deficiency.
- Development of a potential treatment for Myasthenia Gravis, leveraging their expertise in autoimmune diseases.
- A portfolio of novel oncology compounds targeting innovative therapeutic approaches for cancer.
- Research into potential treatments for pediatric growth hormone deficiency, expanding the application of macimorelin.
- Partnerships for the development and commercialization of diagnostic and therapeutic products worldwide.
- Advancements in peptide receptor radionuclide therapy (PRRT) for the treatment of certain tumors.
equipe executiva do Aeterna Zentaris
- Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc.President, CEO & Director
- Mr. Giuliano La FrattaSenior VP of Finance & CFO
- Dr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific Officer
- Dr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical Development
- Dr. Matthias GerlachSenior Vice President Manufacturing and Supply Chain & Head of Production